Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.

Neurobiology of disease - 1 Feb 2011

Simmons Danielle A, Mehta Rishi A, Lauterborn Julie C, Gall Christine M, Lynch Gary

Abstract excerpt

Daily, systemic injections of a positive AMPA-type glutamate receptor modulator (ampakine) have been shown to reduce synaptic plasticity defects in rodent models of aging and early-stage Huntington's disease (HD). Here we report that long-term ampakine treatment markedly slows the progression of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Corpus Striatum
Share to Disease Models, Animal
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Excitatory Amino Acid Agonists

Share to Huntington Disease

Share to Mice, Transgenic

Share to Receptors, AMPA

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 20977939
DOI: 10.1016/j.nbd.2010.10.015
PMCID: PMC3014441

Genes

BDNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20977939-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Brief ampakine treatments slow the progression of Huntington's disease phenotypes in R6/2 mice.PMID 20977939Read ↗

A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice.Semantic proximity Read ↗

XJB-5-131-mediated improvement in physiology and behaviour of the R6/2 mouse model of Huntington's disease is age- and sex- dependent.Semantic proximity Read ↗

Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic miceSemantic proximity Read ↗

The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model.Semantic proximity Read ↗

Early behavioral deficits in R6/2 mice suitable for use in preclinical drug testing.Semantic proximity Read ↗

Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice.Semantic proximity Read ↗

Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling.Semantic proximity Read ↗

Environmental enrichment slows disease progression in R6/2 Huntington's disease mice.Semantic proximity Read ↗

The R6 lines of transgenic mice: A model for screening new therapies for Huntington's diseaseSemantic proximity Read ↗

The novel substituted pyrimidine, KP544, reduces motor deficits in the R6/2 transgenic mouse model of Huntington's disease.Semantic proximity Read ↗

Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.Semantic proximity Read ↗

ABHD6 inhibition rescues a sex-dependent deficit in motor coordination in the HdhQ200/200 mouse model of Huntington’s diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.